This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

LY317615 Plus Capecitabine in Treating Patients With Advanced Solid Tumors

This study has been completed.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Jonsson Comprehensive Cancer Center Identifier:
First received: January 24, 2003
Last updated: October 28, 2015
Last verified: August 2012

RATIONALE: LY317615 may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth and by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining LY317615 with capecitabine may kill more tumor cells.

PURPOSE: Phase I trial to study the effectiveness of combining LY317615 with capecitabine in treating patients who have advanced solid tumors.

Condition Intervention Phase
Adult Solid Tumor Drug: capecitabine Drug: enzastaurin hydrochloride Phase 1

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: A Phase I Dose Escalation Study With Oral LY317615 in Combination With Capecitabine in Advanced Cancer Patients

Resource links provided by NLM:

Further study details as provided by Jonsson Comprehensive Cancer Center:

Enrollment: 16
Study Start Date: December 2002
Study Completion Date: October 2005
Primary Completion Date: November 2004 (Final data collection date for primary outcome measure)
Detailed Description:


  • Determine the maximum tolerated dose and the recommended phase II dose of LY317615 and capecitabine in patients with advanced solid tumors.
  • Determine the safety profile of this regimen in these patients.
  • Determine the pharmacokinetics of this regimen in these patients.
  • Determine, preliminarily, the antitumor activity of this regimen in these patients.
  • Determine the effects of LY317615 on potential angiogenic surrogate markers in these patients.

OUTLINE: This is a dose-escalation study.

Patients receive oral LY317615 daily on days 1-14 (course 1 only). Beginning with course 2, patients receive oral LY317615 daily on days 1-21 and oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of LY317615 and capecitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, additional patients are treated at the recommended phase II dose.

Patients are followed at 30 days after the last dose of study drug.

PROJECTED ACCRUAL: A total of 12-36 patients will be accrued for this study.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed solid tumor that is refractory to standard therapy or for which no standard therapy exists
  • Measurable or evaluable disease
  • 18 and over
  • ECOG 0-2
  • Hematopoietic

    • Absolute neutrophil count at least 1,500/mm^3
    • Platelet count at least 100,000/mm^3
    • Hemoglobin at least 9 g/dL (erythrocyte transfusions allowed)
  • Hepatic

    • Bilirubin no greater than 1.5 times upper limit of normal (ULN)
    • ALT and AST no greater than 2.5 times ULN (5 times ULN if liver metastases present)
  • Renal

    • Creatinine clearance at least 50 mL/min
    • Potassium at least 3.4 mEq/L
    • Calcium at least 8.4 mg/dL
    • Magnesium at least 1.2 mEq/L
  • Cardiovascular

    • QTc interval no greater than 450 msec in males
    • QTc interval no greater than 470 msec in females
    • No other electrocardiogram abnormalities
  • Able to swallow capsules
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 3-6 months after study
  • Endocrine therapy

    • At least 4 weeks since prior anticancer hormonal therapy
    • At least 6 weeks since prior bicalutamide
    • At least 4 weeks since prior flutamide or nilutamide
    • Concurrent luteinizing hormone-releasing hormone analog therapy (e.g., leuprolide or goserelin) allowed for patients with prostate cancer if started before study entry
  • At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin).
  • Radiotherapy

    • At least 4 weeks since prior radiotherapy
    • At least 2 weeks since prior palliative radiotherapy
    • Recovered from prior therapy
  • Other

    • At least 4 weeks since prior investigational anticancer therapy
    • At least 4 weeks since other prior anticancer therapy
    • At least 30 days since prior experimental drugs

Exclusion Criteria:

  • known untreated or symptomatic CNS metastases
  • concurrent hematologic malignancies
  • gastrointestinal disorder that would interfere with oral drug absorption
  • serious concurrent systemic disorder
  • compliance issues that would preclude study
  • geographical conditions that would preclude study
  • active infection
  • prior hypersensitivity to any component of study drugs
  • pregnant or nursing
  • concurrent immunotherapy
  • concurrent routine filgrastim (G-CSF)
  • other concurrent chemotherapy
  • other concurrent hormonal therapy
  • concurrent radiotherapy (including palliative therapy)
  • other concurrent experimental medications
  • other concurrent anticancer therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00052273

United States, California
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, United States, 90095-1781
Sponsors and Collaborators
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)
Principal Investigator: Carolyn Britten, MD Jonsson Comprehensive Cancer Center
  More Information

Responsible Party: Jonsson Comprehensive Cancer Center Identifier: NCT00052273     History of Changes
Other Study ID Numbers: CDR0000258138
P30CA016042 ( U.S. NIH Grant/Contract )
Study First Received: January 24, 2003
Last Updated: October 28, 2015

Keywords provided by Jonsson Comprehensive Cancer Center:
unspecified adult solid tumor
protocol specific

Additional relevant MeSH terms:
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents processed this record on July 21, 2017